Gossamer Bio to Present Updated Seralutinib Data at ATS 2024

SAN DIEGO—Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company at the forefront of clinical-stage research, is dedicated to advancing the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) through the development of seralutinib. The company is set to present the latest findings from its seralutinib TORREY open-label extension study at the American Thoracic Society 2024 International Conference, scheduled for May 17-22 in San Diego, California.

One of the key sessions at the conference will feature an oral presentation on seralutinib. This presentation, which focuses on an inhaled inhibitor targeting PDGFR, CSF1R, and c-KIT, aims to provide new insights into the treatment of pulmonary hypertension. The session is titled "A14: Building Lego(Land): Lessons Learned From Large Scale Clinical Trials In PAH" and is scheduled for Sunday, May 19, from 9:15 a.m. to 11:15 a.m. PT. Dr. Olivier Sitbon, MD, PhD, will present interim results from the Phase 1B and Phase 2 TORREY open-label extension study, offering updates on the ongoing research and potential clinical benefits of seralutinib for patients with PAH. This presentation will be held at the San Diego Convention Center, Room 29A-D (Upper Level).

In addition to the oral presentation, Gossamer Bio will also showcase further data on seralutinib through a series of posters. These posters will provide a deeper dive into various aspects of the TORREY Phase 2 study and its implications for treating PAH. One of the notable poster sessions, titled "D105 Balboa Park Explorers: Translational Science and Epidemiology in PH," will take place on Wednesday, May 22, from 11:00 a.m. to 1:00 p.m. PT. The poster, identified as Poster Board Number 424, is titled "TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve with Treatment." This session will be located in Room 25A-C (Upper Level) of the San Diego Convention Center.

Another important poster presentation, identified as Poster Board Number 318, will be part of the "D109 Now We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular Disease." This session is also scheduled for Wednesday, May 22, from 11:00 a.m. to 1:00 p.m. PT. The poster is titled "Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates with Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial." This presentation will be held in Room 28C-E (Upper Level) of the San Diego Convention Center.

Gossamer Bio continues to make strides in its mission to develop innovative therapies for pulmonary hypertension. By presenting its latest research findings at such a prestigious conference, the company underscores its commitment to advancing medical knowledge and improving patient outcomes. The presentations and posters at the American Thoracic Society 2024 International Conference will provide valuable insights into the efficacy and potential of seralutinib, offering hope for better treatment options for those suffering from PAH and PH-ILD.

Gossamer Bio remains steadfast in its goal of becoming a leader in the biopharmaceutical industry, dedicated to enhancing the lives of patients through cutting-edge research and development.